TABLE 2.

Approved indications for fondaparinux in different countries or regions.

	Indications
China NMPA	①For the prevention of venous thromboembolic events in patients undergoing significant orthopedic surgery of the lower extremities, such as hip fracture, significant knee surgery, or hip replacement
	②For the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction who are not indicated for urgent (<120 min) percutaneous transluminal coronary intervention (PCI)
	③For the treatment of patients with ST-segment elevation myocardial infarction treated with thrombolysis or no other forms of initial reperfusion therapy
Europe EMA	①For the prevention of venous thromboembolic events and adult patients undergoing major leg surgery, such as hip or knee surgery. It can also be used for adult patients at high risk of thrombosis, such as those who are undergoing abdominal surgery or who are forced to stay in bed due to an acute illness
	②To treat superficial venous thrombosis of the lower extremities
	③For the treatment of DVT or PE
	④For the treatment of unstable angina pectoris, ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction in adults
US FDA	①For the prophylaxis of DVT that may lead to PE in patients undergoing HFS, including extended duration of anticoagulation prophylaxis; in patients undergoing hip or knee arthroplasty; and in patients undergoing abdominal surgery who are at risk for thromboembolic complications
	②For the treatment of acute DVT
	③For the treatment of acute PE